



# Introducing Genova's Innovative Methylation Panel

Discussion on Clinical Utility and Case Review

**Michael Chapman, ND**



# **Lahnor Powell, ND, MPH**

**Medical Education Specialist for Genova Diagnostics**



# Michael Chapman, ND


Product Development Manager & Medical Education Specialist  
for Genova Diagnostics



# Technical Issues & Clinical Questions

Please type any technical issue or clinical question into either the “Chat” or “Questions” boxes, making sure to send them to “Organizer” at any time during the webinar.

We will be compiling your clinical questions and answering as many as we can the final 15 minutes of the webinar.



*DISCLAIMER: Please note that any and all emails provided may be used for follow up correspondence and/or for further communication.*



# Need More Resources?

Explore

## WWW.GDX.NET

for more information and educational resources, including...

LEARN **GDX** – Brief video modules

LIVE **GDX** – Previous webinar recordings

GI University – Focused learning modules

MY **GDX** – Order materials and get results

The screenshot shows the Genova Diagnostics website's Medical Education page. At the top, there are social media icons (Twitter, LinkedIn, YouTube, Facebook) and navigation links for Payments, About, Contact, Search, myGDX, and Region. The main header includes the Genova Diagnostics logo and navigation for HOME, CLINICIANS, and PATIENTS. The breadcrumb trail reads Home / Clinicians / Medical Education.

### Medical Education

Genova Diagnostics is an internationally renowned medical testing facility committed to the highest professional standards. The Medical Affairs Team provides educational support in a broad array of formats, including complementary phone consultations to healthcare professionals with Genova Diagnostic accounts. Supplemental educational materials are available for assistance in clinical application and interpretation of Genova Diagnostics tests throughout the site.

- Medical Conferences**: Visit with us at a local medical conference. New locations are published frequently. [More →](#)
- Webinars** (circled in red): Leaders in the field share their expertise on diagnostic and therapeutic approaches to common clinical conditions. [More →](#)
- LearnGDX**: Brief video modules designed to help you understand and clinically apply Genova's broad array of diagnostic testing. [More →](#)
- Educational Modules**: Focused Universities supporting you in your mission to help patients achieve the best possible health. [More →](#)
- Bookstore**: Books recommended by Genova Diagnostics to help support your health and well-being. [More →](#)
- Consultations**: Request a complementary phone session with one of our Medical Education Specialists, available to existing clients. [More →](#)

At the bottom, there are logos for GLfx, NutrEval, and ION, along with a quote: "Providing comprehensive and innovative clinical laboratory services for the prevention, diagnosis and treatment of complex chronic disease..." attributed to Genova Diagnostics.



# Introducing Genova's Innovative Methylation Panel

Discussion on Clinical Utility and Case Review

**Michael Chapman, ND**



# Learning Objectives for this Presentation

- Review the concept of 1-carbon metabolism and methylation reactions
- Discuss the interpretation and application of Genova's Methylation Panel along with case study review
- Apply nutritional and lifestyle therapies as potential therapeutic options for different methylation imbalances



OBJECTIVE





# What is Methylation?

- Transfer of single carbon unit from molecule to molecule
  - This is why methylation is also referred to as “1-carbon metabolism”



4-hydroxyestradiol





4-methoxyestradiol





# What is Methylation?





# What is Methylation?

- What makes this enzymatic reaction any more or less important than the rest?
- “If you want to know how important a single process is to a system, just look at how often that process is used within the system.”
  - Biochemical Proverbs by Michael Chapman, ND
- It’s not the methylation reaction that is special, but rather how many processes absolutely depend on methylation



# What Systems Depend on Methylation?

- Creatine production: skeletal muscle contraction
- DNA and RNA synthesis
- Epigenetic gene regulation
- Hormone regulation and detoxification
- Energy production
- Cell membrane repair
- Lipid metabolism
- Neurotransmitter production
- Nitric oxide production: vascular endothelial function
- Immune function

Moore LD, et al. *Neuropsychopharmacology*. 2013;38(1):23-38.

Brosnan JT, et al. *Acta Biochimica Polonica (English Edition)*. 2004;51:405-14.

Smazal AL, Iowa State University; 2013.


Lawson BR, et al. *Clin Immunol*. 2012;143(1):8-21.


Abu-Lebdeh HS, et al. *J Clin Endocrinol Metab*. 2006;91(9):3344-48.

Schalinske KL, et al. *Adv Nutr*. 2012;3(6):755-62.



# Translating Systems to Symptoms





# METHYLATION PANEL

# Report Review



63 Zillicoa Street  
Asheville, NC 28801  
© Genova Diagnostics

Patient: **Sample Patient**

DOB:  
Sex:  
MRN:

## 3534 Methylation Panel - Plasma & Whole Blood

### Interpretation

| Methylation    | Genetic Pol                |
|----------------|----------------------------|
| Homocysteine ▲ | <b>DOWNREGULATING SNPS</b> |
| SAH ▲          | <b>MTHFR</b>               |
| Methionine ▲   | C677T -+                   |
| Choline ▲      | A1298C -+                  |
| Sarcosine ▲    | <b>COMT</b>                |
|                | V158M ++                   |
|                | <b>MTRR</b>                |
|                | A66G -+                    |
|                | <b>MAT1A</b>               |
|                | D18777A --                 |
|                | <b>SHMT1</b>               |
|                | C1240T -+                  |

### Methylation

**SAM/SAH Ratio** Low

**Methylation Balance** Un-methylated Metabolites

**Met/Sulf Balance** Transsulfuration

Patient ID: **3534 Methylation Panel - Plasma & Whole Blood**

Methodology: LCMSMS & Colometric

### Methylation Cap

| Ratios                               | Value | Reference Range |
|--------------------------------------|-------|-----------------|
| 1. Methylation Index (SAM/SAH Ratio) | 3.3   | 1.0 - 2.0       |
| 2. Methylation Balance Ratio         | 1.08  | 0.5 - 1.5       |
| 3. Met/Sulf Balance Ratio            | 0.62  | 0.2 - 1.0       |
| 4. Betaine/Choline Ratio             | 2.3   | 1.0 - 3.0       |

### Methyl Group Donors

|                               |      |          |
|-------------------------------|------|----------|
| 5. S-adenosylmethionine (SAM) | 109  | 50 - 200 |
| 6. Methionine                 | 36   | 10 - 60  |
| 7. Choline                    | 19.1 | 10 - 30  |
| 8. Betaine                    | 44   | 10 - 80  |
| 9. Serine                     | 147  | 50 - 250 |

### Methyl Group Metabolites

|                                  |       |                |
|----------------------------------|-------|----------------|
| 10. S-adenosylhomocysteine (SAH) | 33    | 10 - 60        |
| 11. Homocysteine †               | 11.3  | 5 - 15         |
| 12. Dimethylglycine (DMG)        | 2.9   | 1.0 - 5.0      |
| 13. Sarcosine                    | 6,368 | 1,000 - 12,000 |
| 14. Glycine                      | 267   | 100 - 500      |


### Transsulfuration Metabolites

|                   |       |             |
|-------------------|-------|-------------|
| 15. Cystathionine | 216   | 100 - 400   |
| 16. Cyst(e)ine    | 323   | 100 - 500   |
| 17. Taurine       | 83    | 30 - 150    |
| 18. Glutathione † | 1,577 | 500 - 3,000 |

†These results are not represented by quintile values.  
Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless and Drug Administration.

Patient ID: **Methylation / Transsulfuration**

### Methylation / Transsulfuration



### Energy Production

Patient ID: **3535 Add-on Methylation Genomics - Buccal sample**

Methodology: DNA Sequencing

### MTHFR C677T 5,10-methylenetetrahydrofolate reductase

| Your Genotype: | Allele 1 | Allele 2 |
|----------------|----------|----------|
| <b>C</b>       | <b>C</b> | <b>T</b> |

**Health Implications**  
• The C677T polymorphism downregulates enzymatic activity, which can limit methylation reactions in the body. The C677T polymorphism results in an increased risk of high homocysteine and an increased tendency for lower folate levels.<sup>1,2</sup>  
• Homozygosity for 677 (++) results in 60-70% reduction in MTHFR enzyme activity. Heterozygosity for 677 (+/-) results in 30-40% reduction in MTHFR enzyme activity.<sup>3</sup>  
• Lower levels of B-vitamin and folate increase the risk of elevated homocysteine related to MTHFR SNPs.<sup>2</sup>  
• Homozygous C677T subjects have higher Hcy levels, while heterozygous subjects have mildly raised Hcy levels compared to controls.<sup>4</sup>  
• MTHFR C677T SNPs have been associated with many disease processes including:  
◦ Cardiovascular disease<sup>5-7</sup>  
◦ Depression and schizophrenia<sup>8,9</sup>  
◦ Increased risk of birth defects and Down's syndrome<sup>10</sup>  
◦ Psoriasis  
◦ Diabetes  
◦ Parkinson's disease

| Genotypes | Amino Acid |
|-----------|------------|
| CC        | Ala Ala    |
| CT        | Ala Val    |
| TT        | Val Val    |

**Amino Acid Position:** 222  
**Alanine to Valine**  
GCC → GTC

**DNA Position:** 894  
TCTGCGGGA **G(C or T)** CGATTTCATC  
Amino Acid Codon

**Rs Number:** rs1801133  
**Location:** Chromosome 1p36.22

**Clinical Considerations**  
• Ensure adequate intake of dark-green leafy vegetables and other B vitamin-rich foods.  
• Evaluate homocysteine, SAM, and SAH levels.  
• Supplementation with methylated folate and folate-rich foods may help lower Hcy and mitigate risk.<sup>11</sup>  
• Evaluate the status of vitamin B-2 and B-3 (MTHFR enzyme cofactors).


| Population Category | CC  | CT  | TT  |
|---------------------|-----|-----|-----|
| EUR                 | 47% | 44% | 9%  |
| EAS                 | 37% | 47% | 16% |
| AFR                 | 81% | 19% | <1% |
| AMR                 | 32% | 52% | 16% |
| SAS                 | 68% | 30% | 2%  |

\*Population frequency data is from 1000 GENOMES project as sourced from NCBI dbSNP. The population categories are listed below:  
**EAS (East Asian):** Han Chinese (Beijing), Japanese (Tokyo), Southern Han Chinese, Chinese Dai, Kinh (Vietnam)  
**EUR (European):** Americans with Northern and Western European Ancestry, Toscani, Finnish, British, Spanish  
**AFR (African):** Nigerian, Kenyan, Gambian, Mendi (Sierra Leone), African Americans, African Caribbeans  
**AMR (Ad Mixed American):** Mexican, Puerto Rican, Colombian, Peruvian  
**SAS (South Asian):** Americans of Gujarati descent (India), Punjabi (Pakistan), Bengali (Bangladesh), Sri Lankan/Indian in UK



# Combined Assessment: A Methylation Panel


- A comprehensive approach to systems biology assessment
- Genotypic and phenotypic evaluation of methylation
- Novel biomarkers and genomics involved in methylation pathway





# Interpretation-at-a-Glance

- 3 Pillars
  - Abnormal biomarkers are categorized as either problems in:
    - Methylation Cycle
      - Consider methylation support
    - Transsulfuration Pathway
      - Consider antioxidant support
  - Middle pillar are SNP results



























# Methylation Panel Genomics





















- Ten genomic SNPs relevant to methylation pathway function
  - MTHFR (2)
  - COMT
  - MTRR
  - MAT1A
  - SHMT1
  - MTR
  - CBS
  - BHMT
  - GNMT

| Genetic Polymorphism   |  |
|--|--|
| DOWNREGULATING SNPS  | UPREGULATING SNPS  |
| MTHFR  | MTR  |
| C677T        | A2756G     |
| A1298C       | CBS  |
| COMT   | C699T      |
| V158M        | BHMT   |
| MTRR   | G742A      |
| A66G         | GNMT   |
| MAT1A  | C1289T   |
| D1877    |  |
| SHMT1  |  |
| C1240T   |  |



# Methylation Panel Genomics


- SNPs are categorized into downregulating or upregulating SNPs
- This means that “positive” findings cause the enzyme to work slower (downregulating) or faster (upregulating)

| Genetic Polymorphism   |  |
|--|--|
| DOWNREGULATING SNPS  | UPREGULATING SNPS  |
| MTHFR  | MTR  |
| C677T        | A2756G   |
| A1298C       | CBS  |
| COMT   | C699T    |
| V158M        | BHMT   |
| MTRR   | G742A    |
| A66G         | GNMT   |
| MAT1A  | C1289T   |
| D1877    |  |
| SHMT1  |  |
| C1240T   |  |





# Methylation Panel Biomarkers (cont)

- Functional Ratios
  - Discussed later
- Methyl Group Donors
  - SAM, Methionine, Choline, and Betaine
- Methyl Group Metabolites
  - SAH, Homocysteine, DMG, and Sarcosine
  - Generally, do not want elevated
- Transsulfuration Metabolites
  - Glutathione you want to be adequate






# Pathway Interpretation – Page 3



# Methylation Pathway Format

- Results placed in pathway format
  - Genomic Results
  - Abnormal Biomarkers
- Allows clinicians to visualize the delicate balance or abnormalities in pathway



# Genomic Results – Pages 4+

- There will be a page for each SNP result
- Patient results at the top left
- General genomic information under patient result
- Commentary box on the right


Patient: PATIENT TEST ID: N2230630 Page 9

3535 Add-on Methylation Genomics - Buccal sample

| MTHFR C677T   | 5,10-methylenetetrahydrofolate reductase |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
|---|--|---------------------|----------|----|----|-------------|-----------|--|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| <p><b>Your Genotype:</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center;">Allele 1</td> <td style="width: 50%; text-align: center;">Allele 2</td> </tr> <tr> <td style="text-align: center; background-color: #0056b3; color: white; font-weight: bold;">C</td> <td style="text-align: center; background-color: #0056b3; color: white; font-weight: bold;">T</td> </tr> <tr> <td style="text-align: center;">Wild Type -</td> <td style="text-align: center;">Variant +</td> </tr> <tr> <td colspan="2" style="text-align: center;">Potential Impact:<br/><b>Downregulation</b></td> </tr> </table>   |  | Allele 1            | Allele 2 | C  | T  | Wild Type - | Variant + | Potential Impact:<br><b>Downregulation</b> |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| Allele 1  | Allele 2                                 |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| C   | T  |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| Wild Type -   | Variant +                                |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| Potential Impact:<br><b>Downregulation</b>  |  |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| <p><b>Health Implications</b></p> <ul style="list-style-type: none"> <li>• The C677T polymorphism downregulates enzymatic activity, which can limit Amethylation reactions in the body. The C677T polymorphism results in an increased risk of high homocysteine and an increased tendency for lower folate levels.*</li> <li>• Homozygosity for 677 (++) results in 60-70% reduction in MTHFR enzyme activity. Heterozygosity for 677 (-/+) results in 30-40% reduction in MTHFR enzyme activity.*</li> <li>• Lower levels of B-vitamin and folate increase the risk of elevated homocysteine related to MTHFR SNPs.*</li> <li>• Homozygous C677T subjects have higher Hcy levels, while heterozygous subjects have mildly raised Hcy levels compared to controls.*</li> <li>• MTHFR C677T SNPs have been associated with many disease processes including:               <ul style="list-style-type: none"> <li>• Cardiovascular disease **</li> <li>• Depression and schizophrenia **</li> <li>• Increased risk of birth defects and Down's syndrome **</li> <li>• Psoriasis</li> <li>• Diabetes</li> <li>• Parkinson's disease</li> </ul> </li> </ul> |  |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| <p><b>Clinical Considerations</b></p> <ul style="list-style-type: none"> <li>• Ensure adequate intake of dark-green leafy vegetables and other B vitamin-rich foods.</li> <li>• Evaluate homocysteine, SAM, and SAH levels.</li> <li>• Supplementation with methylated folate and folate-rich foods may help lower Hcy and mitigate risk.**</li> <li>• Evaluate the status of vitamin B-2 and B-3 (MTHFR enzyme cofactors).</li> </ul>  |  |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| <p><b>* Frequency:</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Population Category</th> <th>CC</th> <th>CT</th> <th>TT</th> </tr> </thead> <tbody> <tr> <td>EUR</td> <td>47%</td> <td>44%</td> <td>9%</td> </tr> <tr> <td>EAS</td> <td>37%</td> <td>47%</td> <td>16%</td> </tr> <tr> <td>AFR</td> <td>81%</td> <td>91%</td> <td>&lt;1%</td> </tr> <tr> <td>AMR</td> <td>32%</td> <td>52%</td> <td>16%</td> </tr> <tr> <td>SAS</td> <td>68%</td> <td>30%</td> <td>2%</td> </tr> </tbody> </table>  |  | Population Category | CC       | CT | TT | EUR         | 47%       | 44%  | 9% | EAS | 37% | 47% | 16% | AFR | 81% | 91% | <1% | AMR | 32% | 52% | 16% | SAS | 68% | 30% | 2% |
| Population Category   | CC                                       | CT                  | TT       |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| EUR   | 47%                                      | 44%                 | 9%       |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| EAS   | 37%                                      | 47%                 | 16%      |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| AFR   | 81%                                      | 91%                 | <1%      |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| AMR   | 32%                                      | 52%                 | 16%      |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| SAS   | 68%                                      | 30%                 | 2%       |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| <p><b>References</b></p> <ol style="list-style-type: none"> <li>1. Yang Q, et al. <i>Am J Clin Nutr</i>. 2012;96(5):1245-1263.</li> <li>2. Garcia-Mingullan CJ, et al. <i>Genes Nutr</i>. 2014;9(6):436.</li> <li>3. Weisberg IS, et al. <i>Atherosclerosis</i>. 2001;166(2):409-416.</li> <li>4. Liew S-C, et al. <i>Eur J Med Genet</i>. 2015;68(1):1-10.</li> <li>5. Zhang P, et al. <i>Angiology</i>. 2015;66(5):422-432.</li> <li>6. Yang KM, et al. <i>Biomed Rep</i>. 2014;2(5):699-708.</li> <li>7. Cui T. <i>Int J Neurosci</i>. 2015.</li> <li>8. Wu YL, et al. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2013;46:78-86.</li> <li>9. Hu CY, et al. <i>J Neural Transm (Vienna)</i>. 2015;122(2):307-320.</li> <li>10. Yadav U, et al. <i>Metab Brain Dis</i>. 2015;30(1):7-24.</li> <li>11. Zhao M, et al. <i>Stroke</i>. 2017;48(5):1183-1190.</li> </ol>  |  |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
| <p><b>General Genomic Information:</b></p> <p><b>Amino Acid Position:</b> 222</p> <p><b>Alanine to Valine</b><br/>G C C → G T C</p> <p><b>DNA Position:</b> 894</p> <p style="text-align: center;">SNP<br/>↓</p> <p>TCTGGGGA <b>G(C or T)</b> CGATTTCATC</p> <p style="text-align: center;">Amino Acid Codon</p> <p><b>Rs Number:</b> rs1801133</p> <p><b>Location:</b> Chromosome 1p36.22</p>  |  |                     |          |    |    |             |           |  |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |

\*Population frequency data is from 1000 GENOMES project as sourced from NCBI dbSNP. The population categories are listed below:  
 EAS (East Asian): Han Chinese (Beijing), Japanese (Tokyo), Southern Han Chinese, Chinese Dai, Kinh (Vietnam)  
 EUR (European): Americans with Northern and Western European Ancestry, Toscani, Finnish, British, Spanish  
 AFR (African): Nigerian, Kenyan, Gambian, Mendi (Sierra Leone), African Americans, African Caribbeans  
 AMR (Ad Mixed American): Mexican, Puerto Rican, Colombian, Peruvian  
 SAS (South Asian): Americans of Gujarati descent (India), Punjabi (Pakistan), Bengali (Bangladesh), Sri Lankan/Indian in UK

© Genera Diagnostics - A. E. Pinar-Simic, PhD, D(ABMCL), Lab Director - CLIA Lic. #300955571 - Medicare Lic. #34-8475 QMETHS




# Methylation Panel Interpretation

Walkthrough

# Interpretation: Where to Begin?

- Lots of places you could start
  - Page 1: Interpretation-at-a-Glance
    - A great overview once you are familiar with the test
  - Page 2: Biomarker Results
    - Helps to categorize the biomarkers and provides quantitative result findings
  - Page 3: Pathway Analysis
    - Great place to start when you are new to methylation testing






**“If you truly love nature, you will find beauty everywhere.” -*Vincent Van Gogh***



Photo by Gabe Swinney, 2018

# 1. Start with Methylation Cycle

- Key takeaway:
  - The methylation cycle is all about making sure there is adequate SAM (S-adenosylmethionine)
  - SAM is overwhelmingly the body's main methyl donor
  - Think of SAM as the body's methylation currency!




Energy Production

Detoxification



# The Basic Methylation Cycle

- There and back again:
  - SAM can donate a methyl group wherever it is needed
  - Becomes SAH (S-adenosylhomocysteine)
  - SAH then breaks down into...
  - Homocysteine





METHYL  
GROUP



# Finishing the Cycle

- Homocysteine **MUST** be converted, or else, it will lead to build-up of SAH
- Main way to recycle SAM is by turning Hcy back into methionine
- This requires:
  - Activated Folate (5-MTHF)
  - Activated B-12
  - Zinc






# Homocysteine

- You may know homocysteine as a marker for cardiovascular risk
- Elevated levels are associated with:
  - Atherosclerosis and coronary artery disease
  - Osteopenia
  - Neurodegenerative conditions
  - Mood disorders
  - IBD and colon cancer risk
- Sound familiar?



# Homocysteine: a Biomarker for Methylation

- Homocysteine is often used as an indicator of methylation status
  - Clinicians aim for optimal: 2-10 $\mu$ mol/L
- Homocysteine must be recycled back into methionine
- Key takeaway!
  - Homocysteine  $\rightarrow$  Higher SAH levels





# Elevated SAH levels

Plasma S-adenosylhomocysteine as a risk factor for cardiovascular disease

David M Kerins, Mark J Koury, Antonietta

## ABSTRACT

**Background:** Although plasma total homocysteine is identified as an independent risk factor for vascular disease in many studies, there is a considerable overlap between patients at risk and control subjects. The difficulty is to be used to distinguish statistically between the two groups if each group is large enough; however, this is not true for individual patients at risk and control subjects.

**Objective:** We investigated the relationship between plasma homocysteine, S-adenosylhomocysteine, and the risk of cardiovascular disease.

**Design:** We measured plasma homocysteine, S-adenosylhomocysteine, and vitamin B-12 in 30 patients with cardiovascular disease and 29 age- and sex-matched control subjects.

**Results:** The homocysteine levels were 11.0 (14.7)  $\mu\text{mol/L}$  for control subjects and 40.0  $\pm$  20.0 (27.0  $\pm$  6.7 (24.5, 30.0)  $\mu\text{mol/L}$ ) for patients with cardiovascular disease. The S-adenosylmethionine levels were 137.8 (137.8)  $\text{nmol/L}$  for control subjects and 110  $\pm$  27 (97, 120)  $\text{nmol/L}$  for patients with cardiovascular disease. Vitamin B-12 did not differ between the two groups.

**Conclusions:** Plasma homocysteine is a much more sensitive marker of cardiovascular disease than is homocysteine. Both plasma homocysteine and S-adenosylhomocysteine are significantly elevated in patients with cardiovascular disease. *Am J Clin Nutr* 2001;74:723-9. Printed in USA. © 2001 American Medical Association

## KEY WORDS

cardiovascular disease, homocysteine, S-adenosylhomocysteine, vitamin B-12

## INTRODUCTION

Elevated plasma total homocysteine (tHcy) is an independent risk factor for vascular disease. The association between abnormal homocysteine metabolism and cardiovascular disease was first reported by Wilcken and coworkers (1). Since then, as pointed out by Ueland et al (2),

*Int J Biochem Cell Biol.* 2015 Oct;67:158-66. doi: 10.1016/j.biocel.2015.06.015. Epub 2015 Jun 24.

## Role of S-adenosylhomocysteine in cardiovascular disease and its potential epigenetic mechanism.

Xiao Y<sup>1</sup>, Su X<sup>2</sup>, Huang W<sup>3</sup>, Zhang J<sup>3</sup>, Peng C<sup>3</sup>, Huang H<sup>3</sup>, Wu X<sup>3</sup>, Huang H<sup>3</sup>, Xia M<sup>4</sup>, Ling W<sup>5</sup>.

### Author information

A chronic elevation in homocysteine levels results in a parallel increase in intracellular or plasma SAH, *which is a more sensitive biomarker of cardiovascular disease than homocysteine and suggests that SAH is a critical pathological factor in homocysteine-associated disorders.* Previous reports indicate that supplementation with folate and B vitamins efficiently lowers homocysteine levels but not plasma SAH levels, which possibly explains the failure of homocysteine-lowering vitamins to reduce vascular events in several recent clinical intervention studies.

Xiao et al. *Int J Biochem Cell Biol.* 2015 Oct;67:158-66.

**KEYWORDS:** Atherosclerosis; Cardiovascular disease; Epigenetic; Homocysteine; S-adenosylhomocysteine

PMID: 26117455 DOI: [10.1016/j.biocel.2015.06.015](https://doi.org/10.1016/j.biocel.2015.06.015)

[Indexed for MEDLINE]



isease

## INVOLVEMENT



that homocystinuria and elevated vascular damage. Homocysteine accompanied an increase in the range from 150 to 200  $\mu\text{mol/L}$ . However, it was not until the 1970s that a model of vascular disease with vessels having a lower concentration of homocysteine and Wilcken's disease. It is a lower homocysteine load that results in a reduction in the methionine in the plasma. Independent cardiovascular disease with vasculature. The report for this study by et al (7) showed plasma homocysteine in peripheral artery disease with plasma homocysteine. The published results are not objective or reliable in the non-polygenic gene associated with

and Medicine (MJK), Nashville, TN, and the Veterans Affairs Medical Center (VAMC), Nashville, TN. National Institutes of Health, Department of Veterans Affairs, Medical Center, Nashville, TN.

to Conrad Wagner, Department of Medicine, Nashville, TN.

Downloaded from <https://academic.oup.com/ajcn/article-abstract/74/6/723/4649904> by guest on 28 January 2019

# SAM/SAH Ratio







# The SAM/SAH Ratio

- Believed to be a good indicator of cellular “methylation capacity”
  - Correlates well with intracellular SAM/SAH
- SAM tends to be under more homeostatic control
  - If you are running low on cash, you will withdraw money from other sources
- Fluctuations tend to be more due to relative SAH concentrations

*Nutrients* 2013, 5, 2457-2474; doi:10.3390/nu5072457

OPEN ACCESS

**nutrients**

ISSN 2072-6643

www.mdpi.com/journal/nutrients

Article

## A Population Model of Folate-Mediated One-Carbon Metabolism

Tanya M. Duncan <sup>1</sup>, Michael C. Reed <sup>2</sup> and H. Frederik Nijhout <sup>1,\*</sup>

<sup>1</sup> Department of Biology, Duke University, Durham, NC 27708, USA; E-Mail: tmk5@duke.edu

<sup>2</sup> Department of Mathematics, Duke University, Durham, NC 27708, USA;

E-Mail: reed@math.duke.edu

\* Author to whom correspondence should be addressed; E-Mail: hfn@duke.edu;

Tel.: +1-919-684-2793; Fax: +1-919-660-7293.

Received: 12 April 2013; in revised form: 29 May 2013 / Accepted: 4 June 2013 /

Published: 5 July 2013

**Abstract:** *Background:* Previous mathematical models for hepatic and tissue one-carbon metabolism have been combined and extended to include a blood plasma compartment. We use this model to study how the concentrations of metabolites that can be measured in the plasma are related to their respective intracellular concentrations. *Methods:* The model consists of a set of ordinary differential equations, one for each metabolite in each compartment, and kinetic equations for metabolism and for transport between compartments. The model was validated by comparison to a variety of experimental data such as the methionine load test and variation in folate intake. We further extended this model by introducing random and systematic variation in enzyme activity. *Outcomes and Conclusions:* A database of 10,000 virtual individuals was generated, each with a quantitatively different one-carbon metabolism. Our population has distributions of folate and homocysteine in the plasma and tissues that are similar to those found in the NHANES data. The model reproduces many other sets of clinical data. We show that tissue and plasma folate is highly correlated, but liver and plasma folate much less so. Oxidative stress increases the plasma S-adenosylmethionine/S-adenosylhomocysteine (SAM/SAH) ratio. We show that many relationships among variables are nonlinear and in many cases we provide explanations. Sampling of subpopulations produces dramatically different apparent associations among variables. The model can be used to simulate populations with polymorphisms in genes for folate metabolism and variations in dietary input.



# Why Haven't We Been Measuring SAM & SAH?

- Plasma concentrations are around 1/500<sup>th</sup> of Hcy
- Need specialized technology to accurately measure SAM and SAH
  - More labs are developing the capacity to measure these
- Stability concerns:
  - SAM & SAH are very unstable molecules
  - Have to be diligent about preserving and handling of samples



**Let's Do a Case!**





# 75 yo Female: “Beth”


- Longstanding pernicious anemia
- Standard American Diet
  - Coffee for breakfast
  - Maybe eats some toast and bacon around lunchtime, or eats fast food
  - Processed microwave dinners
  - Regular nightly wine intake
- Depression/Anxiety
- Osteopenia
- Fatigue
- Osteoarthritis





# Report Results



- Where to start?
  - Low SAM: main methyl donor
  - High SAH: marker for CVD risk and poor methylation recycling
  - SAM/SAH Ratio
- Homocysteine
  - Elevated
- Even methionine is low






# Treatment Considerations

- In this patient there is an obvious backup in SAH/homocysteine recycling
- Main way to recycle SAM is by turning Hcy back into methionine
- Consider:
  - Activated Folate (5-MTHF)
  - Activated B-12
  - Zinc






# Adding Another Layer





# Methylation Back-up Pathway to the Rescue!

- Betaine (*trimethylglycine*) can be used to turn homocysteine back into methionine
- This only takes place in the liver
  - Main pathway happens everywhere
- Betaine is derived from dietary choline
  - Meats, eggs, and beets
- Shunts choline **AWAY** from other choline pathways
  - Acetylcholine, cell membrane repair, etc.








# Report Results

- What about the backup pathway in this patient?
  - DMG is an independent indicator of BHMT (backup pathway) utilization
    - Here DMG is normal
  - Betaine is low
  - Betaine ultimately comes from choline
    - Here choline is normal, but...




| Ratios                               |      |   |  |           |
|--------------------------------------|------|---|--|-----------|
| 1. Methylation Index (SAM/SAH Ratio) | 0.8  | L |  | 2.2-6.4   |
| 2. Methylation Balance Ratio         | 0.93 | L |  | 1.03-1.20 |
| 3. Met/Sulf Balance Ratio            | 0.60 |   |  | 0.55-0.64 |
| 4. Betaine/Choline Ratio             | 3.9  |   |  | 2.6-7.7   |



# Report Results

- What does all this tell me?
  - Despite the fact that there is obvious poor methylation recycling...
  - The backup pathway is not compensating like it should
- Consider betaine (TMG)



| Ratios                               |      |   |  |           |
|--------------------------------------|------|---|--|-----------|
| 1. Methylation Index (SAM/SAH Ratio) | 0.8  | L |  | 2.2-6.4   |
| 2. Methylation Balance Ratio         | 0.93 | L |  | 1.03-1.20 |
| 3. Met/Sulf Balance Ratio            | 0.60 |   |  | 0.55-0.64 |
| 4. Betaine/Choline Ratio             | 3.9  |   |  | 2.6-7.7   |




# The Dance of Betaine & Choline

- Novel biomarkers
- Choline and betaine are “quaternary” ammonium compounds
  - Choline: Eggs, beef, pork, liver, soybean, and wheat germ
  - Betaine: Wheat bran, wheat germ, spinach, and beets
- Choline is used for:
  - Epigenetic gene regulation
  - Precursor to lipoproteins
  - Phospholipids
  - Acetylcholine
- Betaine is used for:
  - Methylation
  - Osmolyte, under cell stress (mainly in kidneys)



# Betaine/Choline


- Choline is a major lipotrophe, responsible for creating VLDL
  - Elevated plasma choline is positively associated with:
    - Triglycerides
    - Glucose
    - BMI
    - Body fat
    - Waist circumference
- Plasma betaine is *negatively* associated with the majority of these risk factors





# Research on the Betaine/Choline Ratio

- Plasma betaine:choline is statistically significant with almost every aspect of metabolic stress
  - Low betaine, high choline is a risk





# Methylation Genomics (SNPs)

How to appropriately apply genomic information clinically






# Single-Nucleotide Polymorphisms (SNPs)

- Common genetic variants
  - Most of us have millions of SNPs
- These SNPs may alter the activity of a particular enzyme
  - Upregulate
  - Downregulate
- Genes do NOT make your destiny!



# Methylation Pathway Genomics

- Remember which SNPs upregulate vs. downregulate
  - Three in the middle upregulate
  - All the rest downregulate
- Remember, SNPs are just a predisposition
  - MTR: actual upregulation of homocysteine conversion
  - BHMT: patient has tendency to under-utilize the backup pathway (makes sense with results)
  - GNMT: patient has tendency to dispose of SAM and make more SAH








# Methylation Pathway Genomics


- SNPs that downregulate:
  - MTHFR A1298C: reduced conversion to activated folate
    - Clinically consider reaching for your 5-MTHF
  - MTRR: predisposition toward slow repair of oxidized (inactive) B12
  - MAT1A: predisposition toward slow conversion of methionine to SAM
    - Consider short-term application of SAMe supplementation?






# Case Analysis Thus Far

- Therapeutic Interventions:
  - Folate (consider 5-MTHF d/t MTHFR SNP)
  - B12 (consider methylcobalamin in this case)
  - Betaine to support backup pathway
  - May also consider SAME short-term
  - Glycine?...to be continued





# Methylation Balance Ratio






# The Methylation Balance Ratio

- Novel functional assessment for overall methylation balance
- Compares 8 different biomarkers
  - 4 biomarkers with a methyl group to give
  - 4 biomarkers that have had a methyl group removed
    - An explanation will be in the support guide

**Methylation Balance Ratio**

| <u>Methylated Metabolites</u> | <u>Un-Methylated Metabolites</u> |
|-------------------------------|----------------------------------|
| SAM                           | SAH                              |
| Methionine                    | Homocysteine                     |
| Betaine                       | DMG                              |
| Serine                        | Sarcosine                        |




- This ratio is unique to GDX and is being researched



# Folate Analytes – Glycine/Serine

- These analytes are tricky because they are involved in so many different biochemical pathways
- Glycine:
  - Needed as glutathione precursor
  - Needed for SAM disposal
- Serine:
  - Primarily used in methylation balance calculation






**Let's Do Another  
Case!**





# 55 yo Male: “George”


- 10 year hx obesity
- Began Paleo Diet 3 mo ago for weight loss
  - Very high meat intake (not particular about quality of meat)
  - Very low complex carbohydrates/Low fiber
- Has been exercising 3-4x per week
  - Mostly anaerobic
- Family History
  - Cardiovascular Disease
  - Alcoholism





# Let's Look at the Pathway

- High SAM/High Methionine
- High Homocysteine
- High Choline, Serine, Glycine
- A lot of these elevations correlate to both *high protein* and *overweight/obesity*






# Over-Methylation and Plasma SAM/SAH

- Many articles report that higher levels of SAM are associated with...
  - Higher BMI
  - Higher protein intake
  - Higher caloric intake
  - Overweight/Obesity
- Is metabolic syndrome an over-methylation disorder?

Zhou et al. *Nutrition & Metabolism* (2018) 15:47  
https://doi.org/10.1186/s12986-018-0283-x

Nutrition & Metabolism

REVIEW Open Access

 CrossMark

## DNA methylation landscapes in the pathogenesis of type 2 diabetes mellitus

Zheng Zhou<sup>1\*</sup>, Bao Sun<sup>2,3\*</sup>, Xiaoping Li<sup>1</sup> and Chunsheng Zhu<sup>1\*</sup>

**Abstract**

Although genetic variations and environmental factors are vital to the development and progression of type 2 diabetes mellitus (T2DM), emerging literature suggest that epigenetics, especially DNA methylation, play a key role in the pathogenesis of T2DM by affecting insulin secretion of pancreatic  $\beta$  cells and the body's resistance to insulin. Previous studies have elucidated how DNA methylation interacted with various factors in T2DM pathogenesis. This review summarized the role of related methylation genes in insulin-sensitive organs, such as pancreatic islets, skeletal muscle, liver, brain and adipose tissue, as well as peripheral blood cells, comparing the tissue similarity and specificity of methylated genes, aiming at a better understanding of the pathogenesis of T2DM and providing new ideas for the personalized treatment of this metabolism-associated disease.

**Keywords:** T2DM, DNA methylation, Insulin secretion, Insulin resistance, Insulin-sensitive organs

**Background**


Type 2 diabetes mellitus (T2DM), characterized by a complex, multifactorial, and chronic condition that often necessitates the use of various medications to achieve normal blood glucose, is a complex endocrine and metabolic disorder with dire consequences for human health and well-being. Globally, the estimated prevalence of T2DM is 415 million people in 2015 worldwide, and this figure is projected to rise to 642 million people by 2040 [1]. Significant advances have been made over the past few decades in the understanding of glucose homeostasis and the pathophysiology of T2DM [2]. However, elaborate molecular mechanisms for its pathology remains far from clear.

Increasing evidence showed that the interaction between several genetic and environmental factors contributed to the risk of developing T2DM by causing certain degrees of insulin resistance and pancreatic  $\beta$ -cell dysfunction [3]. Candidate approaches localized several disease genes, such as transcription factor 7 like 2 (TCF7L2) [4]. Genome-wide association studies and meta-analysis provided new insight into the genetic architecture of T2DM [5, 6]. However, although over 100 genetic loci had been identified, they collectively explained 10% susceptibility to T2DM, implying other possibilities influencing the nature of disease [7]. Epigenetics, in particular DNA methylation, was also implicated in the pathogenesis of T2DM and other complex metabolism-associated diseases by altering the expression of genes [8–10]. Even more, epigenetics built a molecular link between environmental factors and T2DM [9]. This review focused on DNA methylation landscapes in such insulin-sensitive organs as pancreatic islets, skeletal muscle, liver, kidney, brain and adipose tissue, as well as peripheral blood cells (Table 1).

**DNA methylation**

DNA methylation refers to the regulation of gene expression in the presence of impeccable DNA sequences with its patterns set up by DNA methyltransferases (DNMT), including DNMT3A and DNMT3B in early development. More than half of the genes in vertebrate genomes are associated with cytosine-phosphate-guanine (CpG) islands, which is related to the activity of gene transcription [11]. Thus, DNA methylation has been suggested as a natural integrator of genetic susceptibility and environmental exposure in common disease by playing a key role throughout life in tissue specific gene regulation and transcription [12, 13].

\* Correspondence: zhuchunsheng@163.com  
<sup>1</sup>Zheng Zhou and Bao Sun contributed equally to this work.  
<sup>2</sup>Department of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China  
Full list of author information is available at the end of the article

 BMC

© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.



# Over-Methylation: Is it a Thing?

S/Sx associated with over-methylation:


- Anxiety
- Depression
- Panic attacks
- Attention deficit hyperactivity disorder (ADHD)
- Behavior disorders
- Sleep disorders
- Restlessness
- Schizophrenia

- How does it happen?
  - Taking too much folate
  - Enzyme SNPs that upregulate remethylation of homocysteine
- Potential causes:
  - High SAM levels altering neurotransmitter metabolism?
- This has not been fully studied



# Over-Methylation: Is it a Thing?


- What to look for on lab testing
  - Low Homocysteine (<2umol/L)
  - High SAM/SAH
  - High Sarcosine?
- Common clinical intervention:
  - Niacin
  - Glycine
  - Vitamin B-6





# Therapeutic considerations

- Considering his diet and his results:
  - Ensure getting adequate dietary B-vitamins
    - Especially vitamin B12
  - Consider supplementation with Zn
    - SNP toward BHMT upregulation
- Reduce protein intake?
  - Betaine Supplementation?



4. Betaine/Choline Ratio

3.8




2.6-7.7



# Let's Look at One More

- High homocysteine
- Borderline high SAH
- SAM and methionine look good
  - SAM/SAH Ratio & Methylation Balance on the low side
- So what do we consider?
  - Transsulfuration support
  - Minerals: Mg, Zn
  - Vitamins




## Ratios

|                                      |      |  |           |
|--------------------------------------|------|--|-----------|
| 1. Methylation Index (SAM/SAH Ratio) | 3.2  |  | 2.2-6.4   |
| 2. Methylation Balance Ratio         | 1.09 |  | 1.03-1.20 |



# Transsulfuration


Now that you are all experts...





## 2. Moving to Transsulfuration


- What do we see under transsulfuration?
  - Glutathione
    - One of the body's most powerful antioxidants
  - Pyruvate
    - Cellular energy
  - Taurine





# Transsulfuration

- Key takeaway!
- Transsulfuration is upregulated by two critical factors:
- Higher SAM levels
- Oxidative Stress









# Transsulfuration

- Keep in mind:
- SAM availability determines the rate that homocysteine goes through transsulfuration
- Translation...
  - Glutathione production will not take priority over creating SAM for methylation reactions
- Low SAM → Low Glutathione





# Transsulfuration Interpretation





# The Met/Sulf Balance Ratio


- Novel functional assessment for methylation v transsulfuration balance
- Compares 8 different biomarkers
  - 4 biomarkers from methylation pathway
  - 4 biomarkers from transsulfuration pathway

• An explanation will be in the support guide

## Met/Sulf Balance Ratio

| Methylation Metabolites | Transsulfuration Metabolites |
|-------------------------|------------------------------|
| SAM                     | Cystathionine                |
| SAH                     | Cysteine                     |
| Methionine              | Taurine                      |
| Homocysteine            | Glutathione                  |


- This ratio is unique to GDX and is being researched









# Putting it together

- SAM/SAH ratios look okay...
  - However, homocysteine is still high
- Met/Sulf balance is favoring methylation over transsulfuration
  - Remember, prefer to have all ratios toward the middle
    - Unless clinically you have a reason to push a particular pathway



# Blind Case – You Try!

| Methylation   | Genetic Polymorphism  | Transsulfuration   |
|---|---|--|
| SAH ▲<br>Methionine ▲   | <b>DOWNREGULATING SNPS</b><br><b>MTHFR</b><br>C677T -/+<br>A1298C -/+<br><b>COMT</b><br>V158M -/-<br><b>MTRR</b><br>A66G -/+<br><b>MAT1A</b><br>D18777A -/-<br><b>SHMT1</b><br>C1240T -/- | <b>UPREGULATING SNPS</b><br><b>MTR</b><br>A2756G -/+<br><b>CBS</b><br>C699T -/-<br><b>BHMT</b><br>G742A -/+<br><b>GNMT</b><br>C1289T -/+ |
|  |   | Glutathione ▼<br>Cysteine ▲<br>Glycine ▲<br>           |






# Where Do You Start?


- Always start with the analytes that are most clinically significant!

- SAM, SAH, SAM/SAH
  - Then try to determine where the backup is...
- Choline/Betaine Balance
  - Associated with many metabolic risks
- Glutathione Production/Transsulfuration
  - Then try to determine where the backup is...



# Where Do You Start?

- Then widen the lens to look at overall pathway balance
- Methylation Balance Ratio
    - What is contributing most to the imbalance?
  - Met/Sulf Balance Ratio
    - What is contributing most to the imbalance?
  - Genomics
    - Explain why trouble spots may exist and prevention





# Ratios Summary

- SAM/SAH Ratio
  - Most severe alteration of methylation balance
- Methyl Balance Ratio
  - May be able to detect methylation imbalance earlier
  - May indicate needs for vitamin B-12, folate, choline, or betaine
- Met/Sulf
  - Looks at balance between two interdependent pathways
  - May indicate needs for vitamin B-6, magnesium, and antioxidant support





# Treating Methylation Dysfunction



# Methylation and What To Do

- Methylation Imbalances
  - Methylation Support
    - Green leafy vegetables
    - Folate or 5-MTHF
    - Activated vitamin B-12
    - Betaine
    - Zinc
- Transsulfuration Imbalances
  - Glutathione
  - Antioxidants
  - Glycine
  - Vitamin B-6
  - Magnesium
- The Methylation Panel helps clinicians decide which area needs more support
  - We may even get more information to figure out what *forms* of B-vitamins are best for a patient





# Folate

- Dietary intake of folate-rich foods
  - Leafy green vegetables, legumes, citrus fruits, beets, and whole grains
  - People with significant MTHFR SNPs may have difficulty converting dietary folates into 5-MTHF
- Folic acid
  - Lots of debate regarding this supplement
  - Has been vilified recently, perhaps unfairly
- Folinic acid
  - Used with 5-fluorouracil and methotrexate
- 5-MTHF
  - Irreversibly committed to the methylation cycle
  - Potential for over-methylation?



# Vitamin B-12

- Deficiency common among elderly
  - Hypochlorhydria
  - Pernicious anemia
  - *H. pylori* infection
- Dietary sources: meat, poultry, fish, dairy, and eggs
- Methylcobalamin
  - Cyanocobalamin is synthetic and must be converted by the body into methylcobalamin
- Serum B-12 measurements may not tell the whole story
  - Methylmalonic acid



# Vitamin B-6

- Particularly useful if showing poor glutathione production
- Depleted by environmental toxicants and certain medications
  - PCBs
  - Hydrazine
  - Oral contraceptives
- Dietary sources:
  - Potatoes, bananas, meat, and whole grains
- Pyridoxine vs P-5-P
  - Uncertain absorption of P-5-P
  - 10-200 mg/day



# Zinc

- Very common mineral insufficiency
- Used in both main and backup methylation pathways
- Dietary sources: seafood, meats, whole grains, wheat germ, dairy, and legumes
- Competitive inhibition with copper
  - Also bound by calcium intake
  - May be depleted by ACE inhibitors, PPIs, and glucocorticoids



# Choline/Betaine

- Assists with methylation pathway as well as adequate supply of choline for other pathways
- Useful in metabolic syndrome and NASH
- Dietary sources: organ meats, eggs, wheat germ, soybeans, and meat
  - Beets (Betaine)
- Soy lecithin



# Glycine

- Has been used in multiple clinical conditions
  - Anxiety
  - Poor detoxification (glycination pathway)
  - Poor sleep quality
- Indirectly supports methylation pathways
- Tastes great!






# SAMe

- Extensively researched in multiple conditions
- Directly supplies methyl donors
- Concerns:
  - Bipolar and Schizophrenia
  - Over-methylation
  - Expensive
  - Clinical trials use very high doses for mood and musculoskeletal conditions

# Support Materials

- Website Materials:
  - Methylation Pathway Chart
  - Methylation Panel Support Guide
  - Intro to Methylation Video
  - Sample Report
- Case analysis and clinical consultation with medical education specialists
  - 800.522.4762 to schedule



**“If you truly love nature, you will find beauty everywhere.” -*Vincent Van Gogh***



Photo by Gabe Swinney, 2018



**Presenter:**  
**Michael Chapman, ND**

*Explore*

## **WWW.GDX.NET**

*for more information and  
educational resources, including...*

**LEARN GDX** – Brief video modules

**LIVE GDX** – Previous webinar recordings

**GI University** – Focused learning modules

**Conferences** – Schedule of events we attend

**Test Menu** – Detailed test profile information

---

**MY GDX** – Order materials and get results

# *Questions?*



# Upcoming <sup>LIVE</sup> GDX Webinar Topics

Wednesday, September 25<sup>th</sup> 2019

**Lifestyle Medicine and the Methylome**

Kara Fitzgerald, ND,

Register for upcoming <sup>LIVE</sup> GDX Webinars online at [www.GDX.NET/LIVEGDX](http://www.GDX.NET/LIVEGDX)

The views and opinions expressed herein are solely those of the presenter and do not necessarily represent those of Genova Diagnostics. Thus, Genova Diagnostics does not accept liability for consequences of any actions taken on the basis of the information provided.





# Introducing Genova's Innovative Methylation Panel

Discussion on Clinical Utility and Case Review

**Michael Chapman, ND**